Nobody has published a rate, and the honest answer starts there. What has been counted is growth: aesthetic procedures among people who had previously used a GLP-1 grew 53.8% a year after 2021, against a 4% annual fall among post-bariatric patients [1]. That measures who arrives in a surgeon’s office, not what share of users ends up there.
Lose fifty pounds quickly and the skin does not always follow, and some people mind while others do not. The ones who mind and can afford to act on it end up in that office, and the visit is not in anybody’s price comparison. Not even in the careful version of the arithmetic, which prices the drug and the monitoring around it.
What was counted, and what was not
Researchers took a large health-records database, identified people who had aesthetic procedures between 2016 and 2024, and split them by whether they had previously had bariatric surgery or used a GLP-1. [1] Between 2016 and 2021, the mean annual growth rate of procedures among GLP-1 users was 36.1% a year against 27.1% among post-bariatric patients, P=.0026. After 2021, GLP-1 users rose to 53.8% a year, +17.7% with a 95% CI of 10.4% to 25.4%. The post-bariatric group fell to −4% over the same period, a change of −31.1% with a 95% CI of −37.7% to −25.5%.
The complication finding favors the drug
After propensity matching, the post-bariatric patients had the worse surgical course. Hematoma came in at RR 1.99, 95% CI 1.10 to 3.62. Infection at RR 1.37, 95% CI 1.01 to 1.88. Emergency department use at RR 1.54, 95% CI 1.05 to 2.26. All at P < .05.
That is a real point in favor of the drug route and it should be read with the usual discount. These are two very different populations — one had major abdominal surgery and a different weight trajectory — and matching on recorded variables does not make them comparable. The authors call for work on the underlying factors, which is the right request.
What the operation itself is like on the drug
A ten-year review of 373 panniculectomy patients found two results pointing in opposite directions [2]. Delayed wound healing was more than twice as common among GLP-1 users, at 18.5% against 7.5%. Seromas were nearly three times less common, at 4.9% against 14.0%, and both differences survived multivariable adjustment.
Quoting either line alone gives a reader the wrong answer, so the complication profile differs rather than worsens. Slower healing means more dressing changes and more time off work, which is a real cost that never appears on a surgical quote.
Timing is the other variable, and it is the one a patient controls. In an abdominoplasty series, 30-day complications ran 45% with semaglutide continued to the day of surgery, 30% at a two-week stop and 10% at four weeks [3]. Each group held 20 patients, so the hold is a conversation for the surgical team rather than a rule anyone should read off a website.
Why this belongs on a price page
Because body contouring is cash, and insurance covers it rarely and narrowly, usually only where skin causes documented medical problems. A cosmetic procedure after weight loss is paid the way the drug is paid: out of pocket, by the person who bought the drug.
That does not make it a hidden cost of the prescription, and framing it as one would misdescribe it, because most people will not have surgery. The monthly figure on a product page is presented as the cost of the outcome, though, and it is not — it is the cost of the drug. The other things a year of rapid weight loss can lead to belong in the same ledger as everything else nobody itemizes.
What to take from it
Not a reason to avoid the drug, and not a reason to plan surgery, but two narrower things. First, loose skin is a known consequence of fast weight loss and no seller tracked here mentions it, in the same way nobody mentions what happens when you stop. Second, if it matters to you, slower loss and attention to lean mass are the levers that exist, and both are decisions made at the start rather than at the end.
The lean-mass lever has a size attached. Across randomized trials, lean tissue made up between 25% and 39% of the weight lost on these drugs, and adding resistance training brought that share to 17.5% [4]. That is the one intervention that moved the number, and it is bought from a gym rather than from a seller.
Price the drug against what you want from it, not against the best case. The six-month view is the honest starting point, and it is still only the drug.